Active Biotech offentliggör nyemission
05 nov. 2020 02h00 HE
|
Active Biotech
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, JAPAN ELLER KANADA ELLER I NÅGON ANNAN JURISDIKTION DÄR DISTRIBUTION AV DETTA...
Active Biotech announces rights issue
05 nov. 2020 02h00 HE
|
Active Biotech
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR...
Active Biotech Delårsrapport januari – september 2020
05 nov. 2020 01h45 HE
|
Active Biotech
VIKTIGA HÄNDELSER UNDER KVARTAL 3Tasquinimod Första patienten har doserats i monoterapidelen av fas 1b/2a-studien i multipelt myelomDen kliniska studiedesignen i multipelt myelom presenteras på...
Active Biotech Interim report January – September 2020
05 nov. 2020 01h45 HE
|
Active Biotech
IMPORTANT EVENTS DURING THE THIRD QUARTERTasquinimod First patient dosed in the monotherapy part of the phase 1b/2a study in multiple myelomaThe clinical study design for multiple myeloma will be...
Active Biotech Delårsrapport januari – juni 2020
06 août 2020 02h30 HE
|
Active Biotech
Kvartal 2 i korthet Dr Elaine Sullivan, Dr...
Active Biotech Interim Report January - June 2020
06 août 2020 02h30 HE
|
Active Biotech
Second quarter in brief Dr Elaine Sullivan, Dr...
Active Biotech meddelar att första patienten har doserats i fas 1b/2a-studien med tasquinimod för behandling av multipelt myelom
03 août 2020 02h30 HE
|
Active Biotech
Lund Sverige, 3 augusti, 2020 - Active Biotech (NASDAQ STOCKHOLM: ACTI) meddelar idag att den första patienten har doserats i fas 1b/2a-studien med tasquinimod vid behandling för återkommande eller...
Active Biotech announces first patient dosed in phase 1b/2a study of tasquinimod use in treatment of multiple myeloma
03 août 2020 02h30 HE
|
Active Biotech
Lund Sweden, August 3, 2020 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the first patient has been dosed in the phase 1b/2a clinical study of tasquinimod for treatment of relapsed...
Active Biotech tillhandahåller statusuppdatering i projekten
03 juin 2020 02h30 HE
|
Active Biotech
Lund, 3 juni 2020 - Active Biotech (Nasdaq Stockholm: ACTI) tillhandahåller idag en statusuppdatering i projekten i och med den nya inriktningen som kommunicerades i början av februari. Denna...
Active Biotech provides status update in the portfolio projects
03 juin 2020 02h30 HE
|
Active Biotech
Lund, June 3, 2020 - Active Biotech (Nasdaq Stockholm: ACTI) today provides a status update in the projects following the new direction communicated in early February. This abbreviated update is...